DNSP-11
An eleven-residue, C-terminally amidated peptide predicted to be cleaved from the prodomain of the glial cell line-derived neurotrophic factor precursor, studied in rat and nonhuman-primate Parkinson's models with no human trials.
Also referenced as: DNSP11, Dopamine neuron stimulating peptide-11, Dopamine neuron stimulating peptide 11, PPEAPAEDRSL
Also appears in: Other
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the latest vendor-default policy recorded for that UTC day. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when DNSP-11 crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Neuroprotection. Also surfaces under Other for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
DNSP11, Dopamine neuron stimulating peptide-11, Dopamine neuron stimulating peptide 11, PPEAPAEDRSL
No FDA label signal · 0 trials · 10 PubMed results
Current evidence for DNSP-11 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
DNSP-11 has no clinical trials that name it and 10 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-10-28. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-02 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is DNSP-11?
DNSP-11 — dopamine neuron stimulating peptide-11 — is a synthetic undecapeptide with the sequence Pro-Pro-Glu-Ala-Pro-Ala-Glu-Asp-Arg-Ser-Leu, written PPEAPAEDRSL and carrying a C-terminal amide. The sequence is not a drug-design construct: it sits inside the prodomain of the 211-amino-acid human pre-proGDNF precursor, flanked by dibasic sites where prohormone convertases would be expected to cut, and it was predicted on that basis rather than discovered as a free peptide (Bradley et al., PLoS One, 2010;5(3):e9752).
The work behind it was done at the University of Kentucky College of Medicine, in the Department of Anatomy and Neurobiology and the Morris K. Udall Parkinson’s Disease Research Center of Excellence, by a group centered on Luke H. Bradley, Don M. Gash, and Greg A. Gerhardt. The stated motivation was practical: glial cell line-derived neurotrophic factor (GDNF) showed strong restorative effects on dopamine neurons in animals but is a large, heparin-binding protein that diffuses poorly from an infusion site, so a small fragment of its own precursor was attractive as something that might reach tissue more easily.
It reaches the research-peptide market as a GDNF-adjacent neuroprotection compound. That framing should be read carefully — the entire published record is preclinical, and the peptide’s relationship to GDNF is one of sequence origin, not shared receptor pharmacology.
How it works
- Trophic-like effects on primary dopamine neurons, with a flat dose-response. In embryonic day 14 rat ventral mesencephalic cultures, DNSP-11 raised tyrosine hydroxylase-positive cell survival by roughly 75% over control at five days in vitro and increased neurite length (306 µm versus 222 µm) and branches per neuron (4.4 versus 3.1). Unlike GDNF, whose effect fell off at higher concentrations, DNSP-11 behaved similarly from 0.03 to 10 ng/mL (Bradley et al., PLoS One, 2010).
- Protection shows up at the mitochondrial level, and it is not GDNF’s receptor doing it. In the founding paper, DNSP-11 reduced TUNEL positivity and caspase-3 activity in MN9D cells exposed to 6-hydroxydopamine, blocked staurosporine- and gramicidin-induced cytotoxicity in nutrient-deprived B65 cells where GDNF gave no protection, and prevented staurosporine-induced cytochrome c release from mitochondria (Bradley et al., PLoS One, 2010). A follow-up reproduced dose-dependent protection against staurosporine and 3-nitropropionate in HEK-293 cells, a non-neuronal line (Kelps et al., Neuropeptides, 2011;45(3):213–218). Whether a cell-surface receptor sits upstream of these effects has not been excluded — only GDNF’s own co-receptor has.
- No GFRα1 binding — so not the GDNF pathway. Pull-down and ELISA assays detected no interaction between DNSP-11 and GFRα1, the co-receptor GDNF signals through. A pull-down from rat substantia nigra instead recovered sixteen proteins, eleven of them metabolic, including glyceraldehyde-3-phosphate dehydrogenase (Bradley et al., PLoS One, 2010). The receptor, if there is one, has not been identified.
- ERK1/2 phosphorylation as the candidate intracellular step. A single treatment of MN9D dopaminergic cells produced ERK1/2 phosphorylation, offered as a mechanism for the downstream increases in dopamine function (Fuqua et al., Peptides, 2014;54:1–8).
- A separately named rat counterpart with a different readout. The rat homolog of this sequence was described independently in Helsinki as BEP (brain excitatory peptide) and increased synaptic excitability in rat CA1 pyramidal neurons, in a manner sensitive to N-ethylmaleimide, which the authors read as pointing to a G-protein-coupled receptor (Immonen et al., Experimental Neurology, 2008;210(2):793–796).
Research status
Entirely preclinical. There are no registered human studies of DNSP-11 on ClinicalTrials.gov — not completed, not recruiting, not terminated — and no human pharmacokinetic, tolerability, or efficacy data of any kind. Fewer than ten PubMed-indexed primary papers address the peptide, and nearly all come from the originating laboratory or its collaborators.
Rodent work, direct brain delivery. A single 30 µg injection into the substantia nigra of normal rats was taken up into neurons within thirty minutes, with staining fading by three hours and absent at twenty-four, yet at twenty-eight days striatal microdialysis showed basal dopamine risen from 26.0 to 45.8 nM, DOPAC from 3,355 to 6,544 nM, and HVA from 2,419 to 4,516 nM. In unilaterally 6-hydroxydopamine-lesioned rats, a single 100 µg nigral injection cut apomorphine-induced rotation by about half, significant from week one through week four, with nigral tissue dopamine and DOPAC elevated at five weeks (Bradley et al., PLoS One, 2010;5(3):e9752).
A partial non-replication of the dopamine-release finding. The same group, with a Lund University co-author, revisited the question with additional methods and got a mixed answer. Four weeks after a single nigral treatment, microdialysis found no significant change in potassium- or d-amphetamine-evoked dopamine release. High-speed chronoamperometry did detect increased potassium-evoked release in specific striatal subregions, but only at the two-week time point, and spontaneous locomotor activity was unchanged throughout (Fuqua et al., Peptides, 2014;54:1–8). The restorative signal is therefore region- and time-specific and does not hold across measurement techniques.
Intranasal delivery in rats. Repeated intranasal dosing for three weeks increased dopamine turnover in the striatum and substantia nigra of normal rats at the 300 µg level. In 6-OHDA-lesioned rats the same route produced a decrease in d-amphetamine-induced rotation at two weeks, reduced dopamine turnover in the lesioned striatum, and greater sparing of tyrosine hydroxylase-positive neurons — in one specific subregion of the lesioned substantia nigra pars compacta, not across the structure. Radiolabeled peptide distributed diffusely through the brain within thirty minutes (Stenslik et al., Journal of Neuroscience Methods, 2015;251:120–129).
Nonhuman primates. The single primate study is explicitly a methods and proof-of-concept paper. MPTP-treated rhesus macaques received repeated intranasal DNSP-11 with dose escalation over ten weeks while awake and unsedated. The reported outcome is bilateral striatal target engagement inferred from neurochemical changes in dopamine metabolites, with no observable adverse behavioral effects or weight loss, plus diffuse rostral-to-caudal brain distribution of a single 125I-labeled dose (Stenslik et al., Journal of Neuroscience Methods, 2018;303:30–40). No behavioral efficacy endpoint was the primary object of the study, and no formal toxicology program has been published.
Is the endogenous peptide real? This remains open. An affinity-purified polyclonal antibody produced immunoreactivity in rat brain that was spatially and temporally dissociated from mature GDNF: extensive but not exclusive co-localization in postnatal day 10 mesencephalon, and persistent intense signal at three months when GDNF expression is markedly reduced, strongest in the locus coeruleus where GDNF is not expressed (Sonne et al., Journal of Chemical Neuroanatomy, 2019;100:101664). The authors acknowledge that sequence homologues exist, and antibody-based detection of an 11-mer is not the same as isolating it. The 2010 paper stated plainly that the source of the DNSP-11 signal in nigral neurons was not known, and that its antibody could not distinguish the free 11-mer from the proGDNF form; that has not since been resolved.
Work outside Kentucky is thin and off-topic for Parkinson’s. An NIH National Institute on Aging group reported in passing that DNSP11 is a non-aggregating peptide that inhibits fibril formation by islet amyloid polypeptide and amyloid-β in vitro (Liu et al., Biomolecules, 2023;13(1):167) — an amyloid-chemistry observation, not a neuroprotection result. A 2022 Experimental Biology meeting abstract from Nova Southeastern University reported reduced 6-OHDA-induced caspase-3/7 activity and ERK activation in SH-SY5Y cells; it has not appeared as a peer-reviewed full paper.
No clinical development program has been announced, and no regulatory authority anywhere has approved DNSP-11 for any use.
Common dosage forms
- Lyophilized powder in vials, typically at milligram scale, supplied as a research reagent for laboratory use only. This is the research-market format where the compound is listed at all; it is a thinly stocked item.
- Amidated versus free-acid material. Every published activity study used the C-terminally amidated peptide. Non-amidated synthesis of the same eleven residues is a different compound for these purposes, and certificates of analysis are the only way to tell which one a vial contains.
- No intranasal product exists. The 2015 rat and 2018 primate studies used a laboratory solution; no commercial spray or solution is described in the literature.
- No oral form has any published basis, and the peptide’s reported storage stability over one month across several conditions (Kelps et al., Neuropeptides, 2011) refers to solution and powder handling in a laboratory, not to any finished product.
Key considerations
- Zero human evidence, and no program to generate it. There are no DNSP-11 trials on ClinicalTrials.gov and no published human data. The Research Market status reflects the absence of US approval or any development program aimed at approval. Sixteen years after the founding paper, the compound has advanced as far as a ten-week tolerability-and-distribution study in macaques. Material presenting it as a Parkinson’s treatment is describing rat and primate neurochemistry, not a therapeutic result in people.
- The evidence base is one laboratory’s, and it is patented. Discovery, mechanism, and every in vivo study trace to the University of Kentucky group; the 2010 paper declared three pending patents and the 2014 paper four. Independent work on the sequence amounts to the Helsinki BEP hippocampal-excitability report, an in vitro amyloid-aggregation observation, and a conference abstract in a neuroblastoma cell line — none of which measures dopamine neuron survival in a parkinsonian animal. No outside group has reproduced the parkinsonian-model findings.
- The internal record is not consistent. The headline twenty-eight-day dopamine elevation was not reproduced by microdialysis at four weeks in the same laboratory’s follow-up; the chronoamperometry signal appeared only at two weeks and only in subregions; locomotor activity never moved; and the neuroprotective effect in lesioned rats was confined to one subregion of the substantia nigra pars compacta. These are early, fragile signals, not a settled effect.
- GDNF ancestry is not inherited validation. GDNF itself has a long and conflicting clinical record and is not in clinical use, a point restated in a recent Russian-language review of GDNF isoforms (Parshina et al., Zhurnal Voprosy Neirokhirurgii Imeni N.N. Burdenko, 2025;89(6, pt 2):38–43). DNSP-11 also does not bind GFRα1, so it is not a short-peptide stand-in for GDNF signaling — it is a separate and largely uncharacterized pharmacology that happens to originate in the same precursor.
- Several naming traps. DNSP-5 (FPLPA-amide) and DNSP-17 (ERNRQAAAANPENSRGK-amide) are different peptides predicted from the same GDNF precursor, with their own separate literature; DNSP-5 in particular has its own in vitro and in vivo report from the same Kentucky group (Littrell et al., Neuropeptides, 2013;47(1):43–49). The rat homolog is BEP, an abbreviation that collides with many unrelated terms in literature searches. And the “GDNF prodomain” sold as a recombinant protein reagent is the whole prodomain, not this eleven-residue fragment.